Back to results
US 2007/0179119 A1Published application
Solid and crystalline ibandronate sodium and processes for preparation thereof
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsRevital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov
Life of this patent
Estimating the term…
Abstract
The present invention relates to solid amorphous and crystalline forms of ibandronate sodium.
Claims59
Amorphous ibandronate sodium.
A process for preparing amorphous ibandronic sodium comprising the step of spray drying a solution of ibandronate sodium in water.
A crystalline form of ibandronate sodium selected from the group consisting of:
- a) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.7, 5.0, 17.2, 18.3 and 19.5±0.2° 2θ;
- b) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.8, 9.3, 18.5, 23.1, and 36.1±0.2° 2θ;
- c) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.6, 4.8, 5.3, 9.3, and 34.7±0.2° 2θ;
- d) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.9, 5.1, 6.0, 20.0, and 36.4±0.2° 2θ;
- e) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.7, 9.2, 17.4, 18.4, and 19.9±0.2° 2θ;
- f) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.8, 5.7, 17.3, 19.5, and 26.0±0.2° 2θ;
- g) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.6, 9.2, 18.3, 19.6, and 25.6±0.2° 2θ;
- h) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 5.0, 5.9, 17.2, 20.0, and 25.9±0.2° 2θ;
- i) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 5.1, 6.1, 17.3, 20.1, and 21.5±0.2° 2θ;
- j) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 5.1, 6.2, 17.3, 19.7, and 20.1±0.2° 2θ;
- k) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 5.0, 6.1, 17.2, 25.7, and 30.9±0.2° 2θ;
- 1) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.7, 6.0, 17.2, 26.2, and 31.0±0.2° 2θ;
- m) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.9, 6.2, 25.9, 31.0, and 37.1±0.2° 2θ;
- n) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 5.9, 17.1, 19.6, 20.2, and 21.3±0.2° 2θ;
- o) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 6.1, 17.2, 19.6, 20.3, and 21.4±0.2° 2θ;
- p) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 6.1, 17.2, 19.6, 20.1, and 21.5±0.2° 2θ;
- q) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 6.1, 17.3, 19.6, 21.5, and 30.8±0.2° 2θ;
- r) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 6.2, 25.9, 26.7, 31.1, and 37.2±0.2° 2θ;
- s) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 5.3, 6.0, 17.2, 18.7, and 20.0±0.2° 2θ;
- t) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 4.8, 5.1, 5.3, 5.4, and 6.1±0.2° 2θ;
- u) the crystalline form of ibandronate sodium characterized by x-ray reflections at about 6.2, 15.7, 26.3, 32.6, and 35.6±0.2° 2θ.
18 more elements
Crystalline ibandronate sodium solvate.
Crystalline ibandronate sodium alcoholate.
Crystalline ibandronate sodium ethanolate.
Crystalline ibandronate sodium butanolate.
Dependencies are inferred from the claim text.